[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"classical-hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:classical-hodgkin-lymphoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,42,73,101,136,165,188,211,244,277,309,330,352,374,393],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100401698","phase-2-study-of-pembrolizumab-with-bendamustine-in-hodgkin-lymphoma-100401698",false,"NCT04510636","Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma","Phase 2 Study Evaluating the Safety and Efficacy of Pembrolizumab (KEytruda) in Combination With Bendamustine (TREanda) in Relapsed\u002FRefractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Be willing and able to provide written informed consent for the trial and adhere to trial procedures.\n* Be age ≥18 years at the time of signing informed consent.\n* Have histologically confirmed relapsed (disease progression after most recent therapy) or refractory (failure to achieve CR or PR to most recent therapy) classical Hodgkin Lymphoma (RR HL).\n* Must have received at least standard first line chemotherapy for classical Hodgkin Lymphoma, containing an anthracycline, i.e. ABVD or BEACOPP.\n* Must have failed or declined autologous stem cell transplantation (ASCT), or not be a candidate for ASCT (as per institutional criteria).\n* May have received prior therapy with pembrolizumab (or an equivalent checkpoint inhibitor or anti-PD-L1 antibody), but not in combination with bendamustine.\n* May have received a prior autologous stem cell transplant but must be at least ≥100 days post-auto-transplant, and all transplant- related adverse events must have resolved to a grade 1 or less, and patients are not on immunosuppression, and meet all other eligibility criteria.\n* Must have measurable or evaluable disease, as defined as at least one lesion that can be accurately measured in at least 2 dimensions by CT\u002FPET scan. The minimum measurement must be \\>15 mm in the longest dimension or \\>10 mm in the short axis. Baseline FDG-PET scan must be positive (i.e. FDG-avid HL). Measurements must be done within 28 days prior to trial inclusion..\n* Must have Eastern Cooperative Group (ECOG) performance status 0-1.\n* Must have an estimated life expectancy of greater than 90 days.\n* Demonstrate adequate organ and bone marrow function. All screening laboratory tests should be performed within 7 days of treatment initiation.\n* If FOCBP (defined as any female who has experienced menarche and who has not undergone surgical sterilization (i.e. hysterectomy or bilateral oophorectomy) and is not postmenopausal (menopause is defined as 12 months of amenorrhea in a woman over the age of 45 years in the absence of other biological or physiological causes), eligible patients must have a negative pregnancy test within 72 hours prior to the first dose of study treatment. If the urine test is positive, a serum pregnancy test will be required.\n* All participants must be willing to use adequate contraception for the duration of treatment with study drugs and continue for 120 days after the last dose of study drug.\n* If male, and sexually active with FOCBP, must agree to use adequate contraception for the duration of treatment with study drugs and continue for 120 days after the last dose of study drug.\n* Azoospermic male, or male and FOCBP who are continuously not heterosexually active, are exempt from contraceptive requirements. However, they must still undergo pregnancy testing as described.\n* Must be available for treatment, assessment and follow-up.\n\nExclusion Criteria:\n\n* There is known severe (≥ Grade 3) hypersensitivity to pembrolizumab or bendamustine.\n* Patient receiving any other investigational agents, or on current treatment for RR HL, or has participated in a study of an investigational agent and has received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n\nNote: Subjects who have entered the follow-up phase of an investigational trial may participate as long as it has been 4 weeks since the last dose of the previous investigational agent.\n\n* Patient is receiving any other, non-investigational, chemotherapy, radiotherapy, small molecule, or biologic agent within 4 weeks of the first dose of treatment, or who has not recovered (i.e., ≤Grade 1 or to baseline) from AEs due to a previously administered agent.\n* Patient has had a prior monoclonal antibody within 4 weeks prior to first dose of therapy in the study, or who has not recovered from adverse events due to agents administered more than 4 weeks earlier.\n* Patient has received pembrolizumab, or another anti-PD1, or anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4, or anti-OX-40 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with disease progression whilst on therapy, or within 3 months of completion of this line of therapy, without intervening systemic therapy (including chemotherapy, antibody drug conjugates or other targeted agents).\n* Patient has received prior treatment with bendamustine, either as monotherapy or as part of a combination regimen.\n* Patient has undergone prior allogeneic hematopoietic stem cell transplant.\n* Patient has another concurrent active malignancy (excluding non-melanoma skin cancer or carcinoma in situ of the cervix that has undergone potentially curative therapy), and must be disease-free and off treatment for \\> 3 years.\n* Patient has known active central nervous system or meningeal disease.\n* Patients with active or past documented autoimmune disease that has required treatment in the past 2 years.\n* Patient is receiving systemic steroid therapy at a dose of \\> 10 mg\u002Fday of prednisone (or equivalent) for 7 days prior to day 1 of study treatment.\n* Has an uncontrolled co-existing illness, including but not limited to: ongoing or active infection requiring systemic therapy; systemic congestive heart failure Class III or IV by NYHA criteria; unstable angina pectoris or cardiac arrhythmia; in patients status post allogeneic transplantation uncontrolled GVHD.\n* Patient has a history of (non-infectious) pneumonitis that has required steroid treatment, or concurrent active pneumonitis.\n* Patient is pregnant, or nursing, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of pembrolizumab and\u002For bendamustine.\n* Has a known history of Human Immunodeficiency Virus (HIV), active tuberculosis (TB, Mycobacterium tuberculosis), or active hepatitis B or hepatitis C.\n* Patient has received a live vaccine within 30 days prior to first dose of study drugs.\n* Patient is eligible for autologous or allogeneic stem cell transplant, unless patient has declined this, therefore rendering themselves ineligible for stem cell transplantation.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) Hodgkin lymphoma.",[26,27,28],"Classical Hodgkin Lymphoma","Relapsed Cancer","Refractory Cancer","RECRUITING","2026-06-19",{"date":32,"type":33},"2026-06-23","ACTUAL",{"date":35,"type":33},"2021-12-20",{"date":37,"type":20},"2026-11-01",{"name":39,"class":40},"University Health Network, Toronto","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100384670","phase-1-allogeneic-cd30car-ebvsts-in-patients-with-relapsed-or-refractory-cd30-positive-lymphomas-100384670","NCT04288726","Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas","Inclusion Criteria:\n\n1. Diagnosis and clinical course falling into one of the following categories:\n\n   1. Hodgkin lymphoma\n   2. Aggressive non-Hodgkin lymphoma\n   3. ALK-negative anaplastic T cell lymphoma or other peripheral T-cell lymphoma\n   4. ALK-positive anaplastic T cell lymphoma\n2. CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory.\n3. Age 12 to 75.\n4. Bilirubin 2 times (or 3 times if the patient has Gilbert syndrome) or less than the upper limit of normal.\n5. AST 3 times or less than the upper limit of normal.\n6. Estimated GFR \\> 70 mL\u002Fmin.\n7. Pulse oximetry of \\> 90% on room air\n8. EKG shows no significant arrhythmias\n9. Karnofsky or Lansky score of \\> 60%.\n10. Available allogeneic T cells with ≥15% expression of CD30CAR determined by flow-cytometry.\n11. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n12. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n13. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.\n\nExclusion Criteria:\n\n1. Received an investigational cell therapy or vaccine within the past 6 weeks.\n2. Received an investigational small molecule drug within the past 2 weeks.\n3. Received CD30 antibody-based therapy within the previous 4 weeks.\n4. Received gemcitabine-containing chemotherapy within the previous 12 weeks\n5. History of hypersensitivity reactions to murine protein-containing products.\n6. Pregnant or lactating.\n7. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion).\n8. Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg\u002Fday of prednisone.\n9. Active significant, uncontrolled bacterial, viral or fungal infection.\n10. Symptomatic cardiac disease (NYHA Class III or IV disease).","12 Years","75 Years",{"count":52,"type":20},18,[54],"PHASE1","This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK\u002FTL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, the patients are being asked to volunteer in this research study.\n\nIn this study the investigators want to test a type of T cell made from a normal donor. The T cells the investigators will use are called Epstein Barr virus (EBV) specific T cells (EBVSTs) and are cells that the investigators have trained in the laboratory to recognize a EBV which is the virus that causes mono or kissing disease. Some patients with lymphoma have EBV in their cancer cells. Researchers have given T cell lines from normal donor EBVSTs to lymphoma patients who have EBV in their lymphoma cells and have seen responses in about half the patients. The cells have have been generated and are frozen in a bank. The cells are called \"allogeneic\" (meaning the donor is not related to the patient). CD30.CAR in EBV-specific T cells (called allogeneic CD30.CAR-EBVST) from the blood of healthy donors. The investigators are giving the cells to patients with lymphoma cells that express CD30. If the lymphoma cells also express EBV there may be some benefit from targeting both proteins.\n\nThe purpose of this study is to find out the highest safe dose of allogeneic CD30.CAR-EBVST cells given following chemotherapy and used to treat lymphoma. The investigators will learn the side effects of CD30.CAR-EBVST cells in patients and see whether this therapy may help lymphoma patients",[57,26],"Extranodal Natural Killer\u002FT-Cell Lymphoma, Nasal Type",[59,60,61,62],"CD30-Positive Lymphoma","Hodgkin lymphoma","non-Hodgkin lymphoma","CD30 CAR","2026-06-08",{"date":65,"type":33},"2026-06-10",{"date":67,"type":33},"2020-09-16",{"date":69,"type":20},"2037-06-01",{"name":71,"class":40},"Baylor College of Medicine",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":100},"100579327","changing-paragidms-in-the-prognostic-assessment-of-hodgkin-lymphoma-100579327","NCT06822855","Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma","LH_BIO","Inclusion Criteria:\n\n* Age \\>18 anni\n* Written informed consent signed\n\nCohort A\n\n* Age \\>18 years\n* Histologically confirmed diagnosis of relapsed\u002Frefractory classical Hodgkin lymphoma identified during induction or follow-up\n* Available formalin-fixed, paraffin-embedded (FFPE) biopsy at diagnosis and at the time of progression\u002Frelapse\n* Available plasma sample at progression (before the beginning of salvage therapy)\n* Available FDG-PET evaluation at study enrollment\n* Available clinical, laboratory, and radiologic data at diagnosis and relapse\n\nCohort B\n\n* Diagnosis of classical Hodgkin lymphoma\n* Completion of first-line standard systemic treatment (chemotherapy-based or chemoradiotherapy combined modality)\n* Available plasma sample at the end of treatment (at least 30 days from the last chemotherapy)\n* Available FFPE biopsy at diagnosis\n* No further treatment planned\n* Available clinical, laboratory, and radiologic data at diagnosis and response evaluation\n* Patient's willingness to undergo 6 months follow-up plasma sample collection and to attend regular follow-up\n\nCohort C\n\n* Histologically confirmed diagnosis of classical Hodgkin lymphoma\n* Standard treatment as per available guidelines (e.g., ESMO guidelines)\n* Available treatment data, response, and follow-up data\n* Available FFPE biopsy at diagnosis\n* Available FDG-PET evaluation at study enrollment\n\nExclusion Criteria:\n\n* Patients with nodular lymphocyte predominant Hodgkin lymphoma are not eligible; all other subtypes including nodular sclerosis, lymphocyte-depleted, lymphocyte-rich, and mixed cellularity Hodgkin lymphoma may be enrolled.\n* Active HIV, HBV, HCV viral infection\n* Concomitant neoplasm not treated with a curative aim",{"count":81,"type":20},755,"OBSERVATIONAL","Classical Hodgkin's Lymphoma (cHL) is a rare but highly treatable malignancy of the immune system, primarily affecting young adults. Despite significant therapeutic advancements, frontline treatment failure occurs in up to 30% of cases, with relapse or refractory disease affecting over 50% of these patients. The main therapeutic challenge in cHL remains achieving an optimal balance between disease control and reducing long-term adverse effects. Current prognostic tools only partially capture patient heterogeneity, and cHL continues to evolve spatially and temporally throughout the course of the disease. Personalized treatment strategies require novel integrated tools that better monitor tumor complexity and anticipate disease progression.\n\nFluorodeoxyglucose positron emission tomography (FDG-PET) has improved risk stratification in cHL, as metabolic response during or after chemotherapy strongly correlates with disease progression and survival. However, FDG-PET has limitations, including the absence of standardized criteria and the necessity to initiate treatment before response assessment. To overcome these limitations, molecular profiling and radiomic analysis of baseline FDG-PET data may provide deeper insights into tumor biology, improving prognostic accuracy.\n\nThis observational study aims to dissect the genetic and phenotypic heterogeneity of cHL at diagnosis and during disease evolution, with the goal of identifying novel prognostic biomarkers. These findings could lead to better treatment personalization, increasing cure rates while minimizing treatment-related toxicity. The study is based on the hypothesis that correlating DNA profiling at diagnosis, gene expression, and radiomic features may enable the identification of high-risk signatures, refining prognostic models in cHL. Additionally, liquid biopsy represents a non-invasive method for assessing tumor mutational complexity. The analysis of circulating DNA (cDNA) throughout disease progression could provide insights into genetic evolution and help predict overt progression before clinical manifestations occur.\n\nThe primary objective is to define the genetic mutational profile of cHL at disease progression. As secondary objectives, it will evaluate whether liquid biopsy can accurately recapitulate the genetic heterogeneity observed in tumor tissue, determine the predictive accuracy of liquid biopsy in anticipating disease progression, and correlate genomic and radiomic features with patient outcomes to refine risk stratification and therapeutic decision-making.\n\nBy integrating molecular and imaging-based biomarkers, this study aims to enhance personalized treatment strategies, improve risk-adapted therapeutic approaches, and ultimately optimize curability and quality of life for patients with cHL.",[26,85,86],"Classical Hodgkin Lymphoma Recurrent","Classical Hodgkin Lymphoma Refractory",[88,89],"Liquid Biopsy","classical Hodgkin Lymphoma","2026-05-28",{"date":92,"type":33},"2026-05-29",{"date":94,"type":33},"2022-06-23",{"date":96,"type":20},"2026-12",{"name":98,"class":99},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",12,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":119,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100234656","phase-1-a-study-of-pembrolizumab-mk-3475-in-pediatric-participants-with-an-advanced-solid-tumor-or-lymphoma-mk-3475-051keynote-051-100234656","NCT02332668","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051\u002FKEYNOTE-051)","A Phase I\u002FII Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)","Inclusion Criteria:\n\n* Between 6 months and \\\u003C18 years of age on day of signing informed consent is documented.\n* Histologically- or cytologically-documented, locally-advanced, or metastatic solid malignancy or lymphoma that is incurable and has failed prior standard therapy, or for which no standard therapy exists, or for which no standard therapy is considered appropriate\n* Any number of prior treatment regimens\n* Tissue (or lymph node biopsy for rrcHL participants) available from an archival tissue sample or, if appropriate, a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated\n* Advanced melanoma or PD-L1-positive advanced, relapsed, or refractory solid tumor or lymphoma\n* Measurable disease based on RECIST 1.1 (Or based on IWG \\[Cheson, 2007\\] \\[i.e., measurement must be \\>15 mm in longest diameter or \\>10 mm in short axis\\] for rrcHL participants)\n* Participants with neuroblastoma with only metaiodobenzylguanidine (MIBG)-positive evaluable disease may be enrolled\n* Lansky Play Scale ≥50 for participants from 6 months up to and including 16 years of age; or Karnofsky score ≥50 for participants \\>16 years of age\n* Adequate organ function\n* Female participants of childbearing potential should have a negative urine or serum pregnancy test within 72 hours before the first dose of study medication\n* Female participant is not a woman of childbearing potential (WOCBP) or is a WOCBP who is abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of study intervention\n* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Demonstrate adequate organ function.\n\nExclusion Criteria:\n\n* Currently participating and receiving study therapy in, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation\u002Frandomization\n* Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the date of allocation\u002Frandomization\n* Prior systemic anti-cancer therapy including investigational agent within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent\n* Prior radiotherapy within 2 weeks of start of study treatment\n* Known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical carcinoma in situ) with potentially curative therapy, or in situ cervical cancer\n* Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Tumor(s) involving the brain stem\n* Severe hypersensitivity (≥ Grade 3) to pembrolizumab and\u002For any of its excipients\n* Active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy (such as thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is acceptable\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n* Active infection requiring systemic therapy\n* Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of study medication\n* Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent, or any agent directed to another stimulatory or inhibitory T-cell receptor (eg, cytotoxic lymphocyte associated protein-4 \\[CTLA-4\\], OX-40, CD137)\n* Human immunodeficiency virus (HIV)\n* Hepatitis B or C\n* Known history of active tuberculosis (TB; Bacillus tuberculosis)\n* Received a live vaccine within 30 days of planned start of study medication\n* Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Participants who have had an allogeneic hematopoietic transplant \\>5 years ago are eligible as long as there are no symptoms of Graft Versus Host Disease \\[GVHD\\].)\n* History or current evidence of any condition, therapy, or laboratory abnormality, or known severe hypersensitivity to any component or analog of the trial treatment, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study\n* Known psychiatric or substance abuse disorders that would interfere with the requirements of the study","6 Months","17 Years",{"count":111,"type":20},370,[54,23],"Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these:\n\n* Advanced, which means cancer spread in the body or cannot be removed with surgery\n* Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared)\n* Refractory, which means cancer did not respond to previous treatment\n\nPembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away.\n\nWith Amendment 8, enrollment of participants with solid tumors and participants 6 months to under 12 years old with melanoma were closed.\n\nWith Amendment 13, enrollment was closed for participants with relapsed refractory classical Hodgkin lymphoma (rrCHL), microsatellite instabilty-high (MSI-H) solid tumors, tumor-mutational burden-high (TMB-H) solid tumors, and participants 12 years old to \\\u003C18 years old with advanced melanoma.",[115,116,117,26,118],"Melanoma","Lymphoma","Solid Tumor","Microsatellite-instability-high Solid Tumor",[120,121,122,123,124,125],"PD1","PD-1","PDL1","PD-L1","cHL","MSI-H",{"date":127,"type":33},"2026-06-01",{"date":129,"type":33},"2015-03-19",{"date":131,"type":20},"2028-02-02",{"name":133,"class":134},"Merck Sharp & Dohme LLC","INDUSTRY",17,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100467132","phase-1-a-study-of-mgd024-in-patients-with-relapsed-or-refractory-hematologic-malignancies-100467132","NCT05362773","A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies","A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies","Inclusion Criteria:\n\n* Adult patients at least 18 years of age, able to provide informed consent and willing to comply with all study procedures.\n* Participants with\n\n  * primary or secondary acute myeloid leukemia (AML) except acute promyelocytic leukemia,\n  * primary or secondary myelodysplastic syndrome (MDS) with prognostic score of \\>3 and \\\u003C20% bone marrow blasts,\n  * classical Hodgkin lymphoma (cHL),\n  * chronic myelogenous leukemia (CML),\n  * b-cell acute lymphocytic leukemia (B-ALL),\n  * hariy cell leukemia (HCL),\n  * advanced systemic mastocytosis (ASM), or\n  * blastic plasmacytoid dendritic cell neoplasm (BPDCM)\n* Relapsed after or refractory to at least one prior line of therapy and with no available potentially curative treatment option.\n* Evidence of at least 20% of malignant cells with CD123 expression.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.\n* Life expectancy of at least 12 weeks.\n* Acceptable laboratory values, and heart function.\n* Continuing side effects of prior treatment are mild\n* Women and men of childbearing potential must agree to use highly effective forms of contraception throughout the study through 4 months after the last dose of MGD024.\n\nExclusion Criteria:\n\n* Prior treatment with an anti-CD123-directed agent (except patients with BPDCN, who are allowed to have received prior tagraxofusp).\n* Known involvement of central nervous system (CNS) by the disease under investigation.\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient.\n* Systemic anti-cancer therapy, investigational therapy, corticosteroids or other immune suppressive drugs within 14 days of first dose\n* Vaccination with any live virus vaccine within 4 weeks prior to first dose. Inactivated annual influenza and SARS-CoV-2 vaccination are allowed.",{"count":144,"type":20},130,[54],"CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024.\n\nParticipants will receive treatment with MGD024 in consecutive 28-day cycles for a study treatment period of up to 12 cycles (approximately 1 year) or until treatment or study discontinuation criteria are met. Response assessments will be performed after Cycle 1 and then after every even numbered cycle starting with Cycle 2 until progression or study treatment discontinuation. Participants will be checked for side effects throughout the study.",[148,149,26,150,151,152,153,154],"Leukemia, Acute Myeloid","Myelodysplastic Syndromes","Leukemia, B-cell","Leukemia, Hairy Cell","Mastocytosis, Aggressive Systemic","Blastic Plasmacytoid Dendritic Cell Neoplasm","Chronic Myeloid Leukemia","2026-05-20",{"date":157,"type":33},"2026-05-22",{"date":159,"type":33},"2022-07-13",{"date":161,"type":20},"2027-05",{"name":163,"class":134},"MacroGenics",7,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":173,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100640672","phase-1-cd30-car-t-cells-for-low-risk-relapsed-classical-hodgkin-lymphoma-100640672","NCT07575893","CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma","REACH-CD30: Reinduction Therapy Followed by Engineered Autologous CD30.CAR T Cells in Children, Adolescents and Young Adults With Lower-Risk CD30+ Relapsed Classical Hodgkin Lymphoma NYMC 628","REACH-CD30","Inclusion Criteria:\n\n1. Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)\n2. Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo re-induction therapy.\n3. Confirmatory re-biopsy of relapsed CD30+ cHL prior to study entry.\n4. Risk Factors: Patient must meet established low-risk factors:\n\n   Stage at Diagnosis = IA, IIA\n   * 12 months from end of therapy OR 3-12 months from end of therapy with ≤3 cycles of treatment and no radiation NO B symptoms NO extra nodal disease at relapse NO relapse in a prior radiation field Stage at Diagnosis = IB, IIB, IIIA\n   * 12 months from end of therapy NO B symptoms NO extranodal disease at relapse NO relapse in a prior radiation field\n5. Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after study treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \\\u003C 1% failure rate for protection from pregnancy in the product label.\n6. Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 3 months after the cell infusion therapy.\n7. Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n8. Subject is willing and able to comply with study procedures based on the judgement of the investigator.\n9. Planned to undergo reinduction therapy and found to have a favorable response to one line of reinduction therapy. Patients who are refractory to initial reinduction attempts are considered high-risk and thus not eligible for Cell Product Administration and will be removed from study.\n\nExclusion:\n\n1. High-risk relapsed classical Hodgkin Lymphoma with any of the following:\n\n   B symptoms extra nodal disease at relapse relapse in a prior radiation field\n2. Patients under 6 years and over 29 years of age.","6 Years","29 Years",{"count":100,"type":20},[54],"Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.",[26],"NOT_YET_RECRUITING","2026-05-18",{"date":155,"type":33},{"date":183,"type":20},"2026-10-01",{"date":185,"type":20},"2032-12-01",{"name":187,"class":40},"New York Medical College",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":173,"maxAge":174,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":41},"100563524","phase-1-cd30-car-t-cells-post-autohsct-for-poor-risk-hodgkin-lymphoma-100563524","NCT06617286","CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma","MAC-CAR: A Phase 1B\u002FII Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults With Poor-Risk Classical Hodgkin Lymphoma (cHL)","Inclusion Criteria:\n\n* Age between ≥ 6 and ≤ 29.99 years at the time of consent.\n* Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)\n* Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo ASCT. Must meet one of the following:\n\nInduction failure Progressive disease Disease relapse (1st, 2nd or 3rd)\n\n* Confirmatory re-biopsy of relapse\u002Frefractory\u002Fpersistent CD30+ cHL prior to study entry.\n* Risk Factors: Patient must meet 2 or more of the established risk factors:\n\nPerformance score (Karnofsky\u002FLansky) \\\u003C;90% Time from diagnosis to first relapse of \\\u003C1 year Extra nodal involvement at the time of relapse\u002Fprogression High baseline metabolic tumor volume (MTV, \\>60mL) by 18F-fluorodeoxyglucose positron emission tomography (PET)\u002Fcomputed tomography (CT) Chemo resistant disease (Deauville 4-5) after the first re-induction\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria",{"count":196,"type":20},21,[54,23],"Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.",[26],[201,202],"classical Hodgkin lymphoma","CAR T-cells","2026-04-10",{"date":205,"type":33},"2026-04-15",{"date":207,"type":20},"2026-12-01",{"date":209,"type":20},"2040-12-31",{"name":187,"class":40},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":41},"100559370","phase-2-brentuximab-vedotin-for-newly-diagnosed-chl-in-chinese-caya-based-on-petct-assessment-100559370","NCT06563245","Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET\u002FCT Assessment","A Phase II\u002FIII Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET\u002FCT Assessment","Inclusion Criteria:\n\n* Ages \\>=2\\~\\\u003C35 years at the time of enrollment;\n* Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;\n* Adequate organ function;\n* Patients and\u002For their parents or legal guardians sign a written informed consent;\n\nExclusion Criteria:\n\n* Patients with nodular lymphocyte-predominant HL;\n* Patients with an immunodeficiency that existed prior to diagnosis; such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible;Patients known to be positive for HIV are not eligible.\n* Patients who are pregnant; Lactating females who plan to breastfeed.\n* Patients who received systemic corticosteroids within 28 days of enrollment on this protocol","2 Years","35 Years",{"count":221,"type":20},96,[23,223],"PHASE3","Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.",[26,226,227,228,229,230,231,232,233],"Child","Adolescent","Young Adult","Metabolic Response","Survival","Treatment","Brentuximab Vedotin","PET Scan","2026-03-17",{"date":236,"type":33},"2026-03-19",{"date":238,"type":33},"2024-09-25",{"date":240,"type":20},"2039-11-15",{"name":242,"class":243},"Children's Cancer Group, China","NETWORK",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":41},"100620381","european-project-for-ctdna-detection-as-a-biomarker-for-non-invasive-therapy-monitoring-in-paediatric-classical-hodgkin-lymphoma-100620381","NCT07356882","European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma","Non-interventional Research Protocol Involving Human Participants","EURHOLY","Inclusion Criteria:\n\n* Confirmed classical Hodgkin lymphoma (cHL)\n* Children and young adults under the age of 25 years old\n* Signature of informed consent by the patient and\u002For holders of parental authority (depending on the age of the patient)\n* Affiliation to a social security scheme or being beneficiary of such a scheme\n\nExclusion Criteria:\n\n* Previous treatment with chemotherapy or radiotherapy for another cancer\n* Pretreatment of Hodgkin lymphoma (except one treatment with corticosteroid for 7 to 10 days for large or compressive mediastinal tumors).\n* Diagnosis of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)\n* Other concomitant malignancies • Residence outside participating countries in for which long-term follow-up cannot be ensured",{"count":253,"type":20},400,"Classical Hodgkin lymphoma (cHL) accounts for 15% of all cases of cancer in children and adolescents and represents the first cause of cancer during adolescence. Combined multi-modal chemotherapy and modern radiation techniques have transformed cHL in a highly curable cancer. However, up to 10-15% of patients still experience recurrent or primary refractory disease. Thus, there is an unmet need for unravelling the underlying mechanisms of treatment failure and refractoriness in paediatric cHL. Further refinements of treatment strategy are still needed to improve treatment results both in relapse and refractory (R\u002FR) patients and to reduce long-term morbidity and mortality treatment related. Therefore, two main objectives arise: to improve early detection of patients with a high relapse risk to potentially intensify the first line treatment and to better identify low risk patients to further reduce the treatment burden in this good-prognostic population. Initial disease stratification and long-term outcome predictions remain a challenging issue in the field. PET\u002FCT is currently the reference imaging method for initial staging and improves detection of extra nodal disease. None of previous prognostic factors accurately identify patients who will respond adequately and therefore limit the ability to identify patients who should require treatment that is more intensive or new therapeutic approaches like immunotherapy. Taken together, these data emphasize a clear unmet need in the field of cHL. We aim to develop a biomarker tool, which could sharpen the initial risk stratification, improve the assessment of disease evaluation during the treatment and beyond and facilitate the detection of relapse. Over the past decade, as in other malignancies the potential of quantification of circulating tumour DNA (ctDNA) or liquid biopsy, in circulating cell-free DNA (cfDNA) that comprises DNA fragments released from apoptotic or necrotic cells into circulation, has emerged as a promising tool for diagnosis and exploration of the genetic landscape associated with HRS and for response evaluation. Experiences of ctDNA in cHL was first reported in adult cHL. These previous studies paved the way for ctDNA implementation in cHL. First, they contributed to confirm the feasibility to use ctDNA in the detection of tumor-associated mutation. Using paired samples of ctDNA and tumor DNA from HRS cells obtained by microdissection they confirmed the consistent correlation between these two methods. Second, they highlighted the potential role of ctDNA as a surrogate marker for tumor baseline assessment and more importantly for interim evaluation reporting an excellent correlation between the PET\u002FCT result and the presence or the absence of ctDNA after 2 cycles of chemotherapy. Furthermore, Sobesky et al. previously reported that cured patients who were inconsistently judged as interim PET\u002FCT-positive had a more than 2-log drop in ctDNA, whereas relapsing patients who were inconsistently judged as interim PET\u002FCT negative had a less than 2-log drop in ctDNA. These data suggest that ctDNA could be a relevant adjunct to conventional PET\u002FCT approach.",[26],[257,258,259,260,261,262,263,264,265,266,267],"Classical Hodgkin lymphoma","Pediatric oncology","Circulating tumor DNA (ctDNA)","Liquid biopsy","Risk stratification","Minimal residual disease (MRD)","Biomarker","Next-Generation Sequencing (NGS)","Treatment response evaluation","Relapse prediction","PET\u002FCT correlation","2026-01-13",{"date":270,"type":33},"2026-01-21",{"date":272,"type":33},"2025-11-24",{"date":274,"type":20},"2029-11",{"name":276,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":287,"briefSummary":289,"conditions":290,"keywords":293,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":19},"100511026","lifestyles-implemented-survivorship-care-plan-in-lymphoma-survivors-100511026","NCT05934084","Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors","Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors: A Randomized Non-pharmacological Clinical Trial By The Fondazione Italiana Linfomi (FIL)","Inclusion Criteria:\n\n* Age 18-50 at initial treatment;\n* Diagnosis of classical Hodgkin lymphoma (cHL), Diffuse Large B-cell lymphoma (DLBCL) or Primary mediastinal large B-cell lymphoma (PMBCL);\n* Patients in Complete Remission (CR) after first-line therapy \\[ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, doxorubicin , cyclophosphamide, vincristine, procarbazine and prednisone) or ABVD-BEACOPP Pet-2 guided treatment for cHL; R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone) for DLBCL; R-CHOP or R-DA-EPOCH (rituximab- Dose Adapted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) for PMBCL);\n* Patients in remission for a minimum 3 years since the last treatment and a maximum of 10 years;\n* Cumulative doxorubicin\u002F adriamycin dose received of at least 200 mg\u002Fmq (4 cycles of chemotherapy);\n* Availability echocardiogram (ECG) and 2D-STE-echocardiography (Two-dimensional speckle strain echocardiography) performed no later than three months prior to enrollment;\n* Signature of a written informed consent form indicating that the patient understands the purpose of and procedures required for the study and is willing to participate voluntarily in the study.\n\nExclusion Criteria:\n\n* Diagnosis of secondary cancer at baseline, except non-melanoma skin cancers and adequately treated cone-biopsied in situ carcinoma of the cervix;\n* Second line chemotherapy of stem cell transplant;\n* Not able to perform physical activity;\n* Grade \\>\u002F=3 neuropathy;\n* Vertebral fractures or stenosis of the vertebral canal; other bone fracture;\n* Cardiovascular disease: arrhythmia \\>\u002F= grade 2, hypertension \\>\u002F grade 2, left ventricular dysfunction \\>\u002F= grade 2 pericardial disease\u002Feffusion any grade, myocarditis any grade, pulmonary hypertension any grade, restrictive cardiomyopathy any grade valvular hearth disease \\>\u002F= grade 2, right ventricular dysfunction \\>\u002F= grade 2;\n* Venous thromboembolism or arterial thrombosis during last 6 months;\n* Hemorrhage\u002F bleeding \\>\u002F= grade 2 during last 6 months;\n* Chronic lymphedema (arms and\u002F or limbs);\n* Rheumatic disease or inflammatory bowel disease in systemic treatment;\n* Any pleural effusion;\n* If female, the patient is pregnant;\n* Unwilling to comply to all required visits and procedures for the duration of study participation","50 Years",{"count":286,"type":20},552,[288],"NA","This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term lymphoma survivors (in remission for a minimum 3 years since the last treatment and a maximum of 10 years).",[26,291,292],"Diffuse Large B Cell Lymphoma (DLBCL)","Primary Mediastinal Large B-cell Lymphoma (PMBCL)",[294,295,296,297,298,299],"Survivorship Care Plan","Lifestyles implemented-Survivorship Care Plan","Quality of Life","Lymphoma Survivors","Nutritional plan","Physical activity","2026-01-09",{"date":302,"type":33},"2026-01-12",{"date":304,"type":33},"2024-02-26",{"date":306,"type":20},"2026-02-01",{"name":308,"class":40},"Fondazione Italiana Linfomi - ETS",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":316,"targetDuration":4,"studyType":21,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":4},"100586518","phase-2-phase-ii-trial-of-anti-pd-1-antibody-treatment-and-radiotherapy-in-early-stage-favorable-classic-hodgkin-lymphoma-100586518","NCT06916416","Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma","PREFer","Inclusion Criteria:\n\n* Histologically proven first diagnosis of cHL\n* Stage I-II without risk factors\n\n  * Large mediastinal mass\n  * Extranodal involvement\n  * Elevated erythrocyte sedimentation rate (ESR)\n  * Involvement of ≥ 3 nodal areas\n\nExclusion Criteria:\n\n* Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma,\n* Prior cHL-directed treatment\n* Prior chemotherapy, RT or allogeneic stem cell\u002Fsolid organ transplant\n* Prior or concurrent disease precluding protocol treatment (for details see section 4.2)\n* Pregnancy or breastfeeding\n* Non-compliance",{"count":317,"type":20},50,[23],"By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.",[26],"2025-03-31",{"date":323,"type":33},"2025-04-08",{"date":325,"type":20},"2025-06",{"date":327,"type":20},"2028-06",{"name":329,"class":40},"University of Cologne",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":16,"minAge":337,"maxAge":17,"enrollmentInfo":338,"targetDuration":4,"studyType":21,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":41},"100581304","phase-2-sintilimab-plus-avd-in-pediatric-lowmoderate-risk-hodgkin-lymphoma-a-phase-ii-study-100581304","NCT06848569","Sintilimab Plus AVD in Pediatric Low\u002FModerate Risk Hodgkin Lymphoma: A Phase II Study","Prospective, Single-Arm, Multicenter, Phase II Study of Sintilimab in Combination With AVD for Pediatric and Adolescent Low\u002FModerate Risk Classical Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Age between 1 and 18 years, regardless of gender.\n2. Low-risk group: Must be a newly diagnosed patient with pathologically confirmed classical Hodgkin lymphoma, Ann Arbor stage IA or IIA, without bulky disease (defined as a mediastinal mass diameter \\> 1\u002F3 of the chest diameter on an upright chest X-ray or any lymph node with a maximum transverse diameter \\> 6cm outside the mediastinum). Intermediate-risk group: Must be a newly diagnosed patient with pathologically confirmed classical Hodgkin lymphoma, Ann Arbor stage IB, IAE, IIAE, IIIA with or without bulky disease, or IA or IIA with bulky disease, or IIB without bulky disease (B symptoms defined as: weight loss \\> 10%; recurrent unexplained fever with temperature \\> 38°C; night sweats).\n3. Presence of measurable lesions.\n4. For male participants with reproductive potential, they must agree to the following during the intervention period to be eligible: not donating sperm, practicing abstinence according to their preferred and usual lifestyle, and agreeing to maintain abstinence or use contraception as required by the protocol unless proven to be azoospermic.\n5. Female participants who are not pregnant or breastfeeding, non-reproductive potential women, or those who agree to use approved contraception for at least 120 days after the last research intervention, and agree not to donate eggs (ova, oocytes) to others or freeze\u002Fstore for their own reproduction during this period.\n6. General condition: Lansky score ≥ 50 (age \\\u003C 16 years), Karnofsky score ≥ 50 (age ≥ 16 years).\n7. Laboratory tests during the screening period should meet the following conditions:Absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL (ANC ≥ 1.0×10\\^9\u002FL if bone marrow involvement),Platelet count (PLT) ≥ 75×10\\^9\u002FL (PLT ≥ 50×10\\^9\u002FL if bone marrow involvement),Bilirubin ≤ 1.5 times the upper limit of normal (ULN) Creatinine ≤ 1.5 times ULN (calculated according to the standard Cockcroft-Gault formula).ALT\u002FAST ≤ 3 times ULN (can be relaxed to 5 times ULN if liver metastasis is present)\n8. Able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during participation in the study.\n9. Parents\u002Flegal guardians of pediatric or adolescent subjects have the ability to understand, consent, and sign the informed consent form (ICF) and applicable child assent form before any protocol-related procedures are initiated; subjects are able to express consent in the presence of parents\u002Flegal guardians (if applicable).\n\nExclusion Criteria:\n\n1. History of solid organ transplantation at any time or allogeneic hematopoietic stem cell transplantation within the past 5 years.\n2. Female participants with reproductive potential who test positive for pregnancy on a urine pregnancy test within 24 hours before the first dose.\n3. Baseline left ventricular ejection fraction \\\u003C 50% or left ventricular short-axis shortening fraction \\\u003C 27%.\n4. Previous treatment with anti-programmed death (PD-1), anti-programmed death ligand 1 (PD-L1), or anti-PD-L2 drugs, or drugs targeting another co-inhibitory T cell receptor.\n5. Received any systemic anti-cancer treatment, including investigational drugs for the current diagnosis, before enrollment.\n6. Received live or attenuated vaccines within 30 days before the first research intervention. Inactivated vaccines are allowed.\n7. Received investigational drugs or used investigational devices within 4 weeks before the research intervention.\n8. Diagnosed with lymphocyte-predominant Hodgkin lymphoma.\n9. Diagnosed with immune deficiency or receiving chronic systemic corticosteroid therapy or any other form of immunosuppressive treatment within 7 days before the first administration of sintilimab.\n10. Known progression of other malignancies or requiring active treatment within the past 3 years.\n11. Presence of detectable central nervous system metastasis and\u002For carcinomatous meningitis on radiology at the time of diagnosis.\n12. Severe hypersensitivity (≥ grade 3) to any research treatment, including excipients.\n13. Active autoimmune disease requiring systemic treatment within the past 2 years.\n14. History of (non-infectious) pneumonia\u002Finterstitial pneumonitis requiring corticosteroid treatment or currently suffering from pneumonia\u002Finterstitial lung disease with active infection requiring systemic treatment.\n15. Known history of human immunodeficiency virus (HIV) infection.\n16. Known history of hepatitis B or active hepatitis C virus infection.\n17. Presence of any disease, treatment, or laboratory abnormality results that may confound study results, interfere with the subject's participation throughout the study, or, in the opinion of the treating investigator, is not in the subject's best interest to participate in the study.\n18. Known mental illness or substance abuse disorder that would interfere with cooperation with the study requirements.\n19. Patient has not fully recovered from major surgery or has persistent postoperative complications.\n20. Other conditions that the investigator considers should be excluded.","1 Year",{"count":339,"type":20},73,[23],"Study Purpose: To evaluate the efficacy and safety of sintilimab in combination with AVD chemotherapy for the treatment of pediatric and adolescent patients with low-to-intermediate risk classical Hodgkin lymphoma (cHL).\n\nStudy Design: This is a prospective, single-arm, multicenter, phase II clinical trial.\n\nStudy Population: Pediatric and adolescent patients aged 1 to 18 years, diagnosed with classical Hodgkin lymphoma, and classified as low-to-intermediate risk according to the Ann Arbor staging system.\n\nTreatment Plan: Sintilimab in combination with AVD chemotherapy, administered every two weeks for a planned 4-6 cycles.",[26],"2025-02-26",{"date":345,"type":33},"2025-02-27",{"date":347,"type":33},"2024-10-23",{"date":349,"type":20},"2031-10-23",{"name":351,"class":40},"Sun Yat-sen University",{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":21,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":41},"100426872","phase-2-pembrolizumab-in-combination-with-salvage-chemotherapy-for-first-relapsed-or-refractory-classical-hodgkin-lymphoma-100426872","NCT04838652","Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","Phase II Trial of Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","Pembro-CORE","Inclusion Criteria:\n\n* Histologically confirmed first relapse of cHL or primary refractory cHL\n\nExclusion Criteria:\n\n* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma","65 Years",{"count":362,"type":20},29,[23],"The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r\u002Fr cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP). Synergistic effects of conventional agents with checkpoint inhibition may facilitate a highly effective therapy with limited toxicity, which might eventually substitute the very toxic high-dose chemotherapy (HDCT).",[26],"2024-08-21",{"date":368,"type":33},"2024-08-23",{"date":370,"type":33},"2024-03-05",{"date":372,"type":20},"2028-05",{"name":329,"class":40},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":21,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":41},"100426811","phase-2-phase-ii-trial-of-individualized-immunotherapy-in-early-stage-unfavorable-classical-hodgkin-lymphoma-100426811","NCT04837859","Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma","INDIE","Inclusion Criteria:\n\n* Age 18-60 for the main trial cohort\n* Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort\n* First diagnosis of treatment-naïve cHL\n* Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d, stage IIB with risk factors c-d):\n\n  1. large mediastinal mass\n  2. extranodal lesion(s)\n  3. elevated erythrocyte sedimentation rate\n  4. ≥ 3 nodal areas\n\n     Exclusion Criteria:\n* Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and\u002For central nervous system involvement of lymphoma",{"count":382,"type":20},120,[23],"The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.",[26],"2024-07-25",{"date":388,"type":33},"2024-07-26",{"date":390,"type":33},"2024-05-24",{"date":372,"type":20},{"name":329,"class":40},{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":21,"phases":402,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":41},"100508464","phase-2-a-study-of-zimberelimabgls-010-combined-with-avd-for-newly-diagnosed-early-stage-hodgkins-lymphoma-100508464","NCT05900765","A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma","A Multicenter, Open-label Phase II Study on the Treatment of Newly Diagnosed Early-stage Hodgkin's Lymphoma With Zimberelimab (GLS-010) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET\u002FCT","Inclusion Criteria:\n\n1. Diagnosed with primary classical Hodgkin lymphoma (HL) based on histopathology.\n2. Stage I-II .\n3. At least one measurable target lesion（Lugano 2014）.\n4. Age 18 years or older (including 18 years) to 45 years (recent fertility requirements and concern about chemotherapy side effects), or age \\>60 years (older patients who are frail and unwilling to undergo chemotherapy), male or female.\n5. ECOG PS 0-3,\n6. Expected survival ≥ 3 months.\n\nExclusion Criteria:\n\n1. Hodgkin's lymphoma with nodular lymphocyte predominant type.\n2. Patients who are scheduled to undergo subsequent autologous stem cell transplantation.\n3. Contraindications to radiotherapy.\n4. With central nervous system (meningeal or parenchymal) involvement.\n5. Contraindications to immune checkpoint inhibitors.",{"count":401,"type":20},54,[23],"This is a multicenter, open-label single-arm phase II study to evaluate the efficacy and safety of Zimberelimab (GLS-010) combined with AVD for newly diagnosed early-stage Hodgkin's lymphoma under the guidance of PET\u002FCT.",[26],[406,407,408],"Zimberelimab","PD-1 Checkpoint Inhibitor","AVD","2023-06-15",{"date":411,"type":33},"2023-06-18",{"date":413,"type":33},"2023-06-14",{"date":415,"type":20},"2026-06-30",{"name":351,"class":40}]